Firm announced that it is investing $25 mil. to expand research facilities at Merrell Dow Research Institute in Cincinnati. Two new buildings, the first to be completed in October 1985 and the second in mid-1987, will house research focusing "on rapidly evolving areas such as molecular biology, the structure and functions of proteins and on enzyme biochemistry," the firm said. Expansion is expected to add 200 new research and support personnel jobs
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.